Report cover image

Global Biosimilars Market - 2024-2033

Publisher DataM Intelligence 4Market Research LLP
Published Feb 27, 2026
Length 200 Pages
SKU # DTAM21131750

Description

Global Biosimilars Market Overview:
The Global Biosimilars Market was valued at US$ 30.30 Billion in 2024 and is anticipated to reach US$ 99.3 Billion by 2033, at a CAGR of 0.141 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Biosimilars Market.

This report delivers a comprehensive overview of the Global Biosimilars Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Biosimilars Market. The Global Biosimilars Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Global Biosimilars Market Scope:
By Drug Class
• Monoclonal Antibodies (mAbs)
• Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors
• Granulocyte Colony-Stimulating Factor (G-CSF)
• Insulin
• Erythropoietin
• Human Growth Hormone
• Follitropin
• Interferons
• Anti-Vascular Endothelial Growth Factor
• Other Drug Classes

By Therapeutic Area
• Oncology
• Immunology & Autoimmune Diseases
• Metabolic Diseases (including diabetes)
• Neurology
• Infectious Diseases
• Rare Diseases
• Others

By Manufacturing Modality
• Mammalian Cell-Based Biosimilars
• Microbial-Based Manufacturing
• Plasma-Derived Manufacturing
• Other Manufacturing Platforms

By Route of Administration
• Intravenous
• Subcutaneous
• Intramuscular
• Others

By End-User
• Hospitals & Specialty Clinics
• Infusion Centers
• Specialty Pharmacies
• Others

Key Players
• Pfizer, Inc.
• Amgen Inc.
• Novartis AG (Sandoz division)
• Samsung Bioepis Co., Ltd.
• Celltrion, Inc.
• Biocon Limited
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• Dr. Reddy’s Laboratories Ltd.
• STADA Arzneimittel AG
• Fresenius Kabi AG
• Apotex Inc.

Major Highlights
This report delivers a comprehensive overview of the Global Biosimilars Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Biosimilars Market. The Global Biosimilars Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

200 Pages
1. Definition and Overview
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. Executive Summary
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Government-Led Switching and Tender Policies Accelerating Biosimilars Adoption in Public Health Systems
3.1.1.2. Patent Expiry Wave of Blockbuster Biologics Unlocking Multi-Billion-Dollar Biosimilars Entry Windows
3.1.1.3. Hospital and Payer Cost-Containment Programs Prioritizing Biosimilars in Treatment Protocols
3.1.2. Restraints
3.1.2.1. Interchangeability and Physician Confidence Barriers Slowing Automatic Substitution
3.1.2.2. High Analytical and Clinical Comparability Costs Limiting New Entrant Participation
3.1.2.3. Complex Cold-Chain and Bioprocess Manufacturing Requirements Increasing Operational Risk
3.1.3. Opportunity
3.1.3.1. Rapid Expansion of Biosimilars in Emerging Therapeutic Segments such as Ophthalmology and Rare Diseases
3.1.3.2. Strategic Licensing and Co-Development Agreements Between Innovators and Biosimilars Developers
3.1.3.3. Growth of Local Biomanufacturing Hubs in Asia and Latin America Supporting Export-Oriented Drug Class
3.1.4. Trends
3.1.5. Impact Analysis
4. Industry Analysis
4.1. Porter’s Five Force Analysis – Global Biosimilars
4.2. Geopolitical & Supply Chain Exposure
4.3. Social & Patient-Centric Factors
4.4. Economic Factors
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Biosimilars Ecosystem Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Global Biosimilars Market
5. By Drug Class
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
5.1.2. Market Attractiveness Index, By Drug Class
5.2. Monoclonal Antibodies (mAbs)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors
5.4. Granulocyte Colony-Stimulating Factor (G-CSF)
5.5. Insulin
5.6. Erythropoietin
5.7. Human Growth Hormone
5.8. Follitropin
5.9. Interferons
5.10. Anti-Vascular Endothelial Growth Factor
5.11. Other Drug Classes
6. By Therapeutic Area
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
6.1.2. Market Attractiveness Index, By Therapeutic Area
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Immunology & Autoimmune Diseases
6.4. Metabolic Diseases (including diabetes)
6.5. Neurology
6.6. Infectious Diseases
6.7. Rare Diseases
6.8. Others
7. By Manufacturing Modality
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
7.1.2. Market Attractiveness Index, By Manufacturing Modality
7.2. Mammalian Cell-Based Biosimilars*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Microbial-Based Manufacturing
7.4. Plasma-Derived Manufacturing
7.5. Other Manufacturing Platforms
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Intravenous *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Subcutaneous
8.4. Intramuscular
8.5. Others
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals & Specialty Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Infusion Centers
9.4. Specialty Pharmacies
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.8.1. US
10.2.8.2. Canada
10.2.8.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.8.1. Germany
10.3.8.2. UK
10.3.8.3. France
10.3.8.4. Russia
10.3.8.5. Italy
10.3.8.6. Spain
10.3.8.7. Norway
10.3.8.8. Netherlands
10.3.8.9. Sweden
10.3.8.10. Denmark
10.3.8.11. Belgium
10.3.8.12. Switzerland
10.3.8.13. Austria
10.3.8.14. Poland
10.3.8.15. Finland
10.3.8.16. Rest of Europe
10.4. Latin America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.8.1. Brazil
10.4.8.2. Argentina
10.4.8.3. Rest of Latin America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.8.1. China
10.5.8.2. India
10.5.8.3. Japan
10.5.8.4. Australia
10.5.8.5. South Korea
10.5.8.6. New Zealand
10.5.8.7. Indonesia
10.5.8.8. Malaysia
10.5.8.9. Philippines
10.5.8.10. Singapore
10.5.8.11. Thailand
10.5.8.12. Vietnam
10.5.8.13. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.6.8.1. UAE
10.6.8.2. Saudi Arabia
10.6.8.3. South Africa
10.6.8.4. Israel
10.6.8.5. Egypt
10.6.8.6. Turkey
10.6.8.7. Qatar
10.6.8.8. Kuwait
10.6.8.9. Oman
10.6.8.10. Bahrain
10.6.8.11. Rest of Middle East and Africa
11. Competitive Landscape Analysis
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
11.4. Partner Identification Analysis
11.5. Investment & Funding Landscape
11.6. Strategic Alliances & Innovation Pipelines
12. Company Profiles
12.1. Pfizer, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.3. Revenue Analysis
12.1.4. Pricing Analysis
12.1.5. SWOT Analysis
12.1.6. Recent Developments
12.1.6.1. Major Deals
12.1.6.2. M&A
12.1.6.3. Collaboration
12.1.6.4. Acquisition
12.1.6.5. Joint Ventures
12.1.6.6. Innovations
12.1.7. Recent News
12.1.7.1. Events
12.1.7.2. Conferences
12.1.7.3. Symposiums
12.1.7.4. Webinars
12.2. Amgen Inc.
12.3. Novartis AG (Sandoz division)
12.4. Samsung Bioepis Co., Ltd.
12.5. Celltrion, Inc.
12.6. Biocon Limited
12.7. Viatris Inc.
12.8. Teva Pharmaceutical Industries Ltd.
12.9. Boehringer Ingelheim International GmbH
12.10. Merck KGaA
12.11. F. Hoffmann-La Roche Ltd.
12.12. Dr. Reddy’s Laboratories Ltd.
12.13. STADA Arzneimittel AG
12.14. Fresenius Kabi AG
12.15. Apotex Inc. (LIST NOT EXHAUSTIVE)
13. Global Biosimilars Market – Research Methodology
13.1. Research Data
13.1.1. Secondary Data
13.1.2. Primary Data
13.1.3. CAGR Analysis
13.2. Market Size Estimation Methodology
13.2.1. Bottom-Up Approach
13.2.2. Top-Down Approach
13.3. Market Breakdown & Data Triangulation
13.4. Research Assumptions
13.5. Limitations
14. Appendix
14.1. About Us and Services
14.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us